Your browser doesn't support javascript.
loading
CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis.
Thacker, Seth G; McWilliams, Ian L; Bonnet, Beatrice; Halie, Lydia; Beaucage, Serge; Rachuri, Swaksha; Dey, Ranadhir; Duncan, Robert; Modabber, Farrokh; Robinson, Stephen; Bilbe, Graeme; Arana, Byron; Verthelyi, Daniela.
Afiliação
  • Thacker SG; Laboratory of Immunology, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.
  • McWilliams IL; Laboratory of Immunology, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.
  • Bonnet B; Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.
  • Halie L; Laboratory of Immunology, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.
  • Beaucage S; Laboratory of Biological Chemistry; Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.
  • Rachuri S; Laboratory of Immunology, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.
  • Dey R; Laboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.
  • Duncan R; Laboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.
  • Modabber F; Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.
  • Robinson S; Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.
  • Bilbe G; Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.
  • Arana B; Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.
  • Verthelyi D; Laboratory of Immunology, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.
PLoS Negl Trop Dis ; 14(2): e0008050, 2020 02.
Article em En | MEDLINE | ID: mdl-32109251
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oligodesoxirribonucleotídeos / Leishmaniose Cutânea Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: PLoS Negl Trop Dis Assunto da revista: MEDICINA TROPICAL Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oligodesoxirribonucleotídeos / Leishmaniose Cutânea Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Revista: PLoS Negl Trop Dis Assunto da revista: MEDICINA TROPICAL Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos